Incretin & pharmacology

Mouse hypothalamus — risperidone (bulk RNA-seq)

Mus musculus · Whole hypothalamus · bulk RNA-seq

GSE158751
Explore this datasetView in dataset library

Selected data and study scope

This dataset contains bulk RNA-seq data from Mus musculus, sampled from whole hypothalamus. The default comparison examines gene expression in Risperidone relative to Control.

The explorer includes 1 track and 1 comparison for this dataset.

The default track, Whole hypothalamus, includes 7 Control samples and 7 Risperidone samples in this comparison. These are analysis sample counts. Check the source for biological replication and pooling.

Interpretation and limitations

The measurement combines expression from the cells in the tissue sample. A difference in tissue expression alone does not identify which cell type contributes to it.

Expression values are CPM (TMM-normalized): counts per million on library sizes adjusted by the TMM factors of the study’s own edgeR fit. This scale adjusts for library size and composition, not gene length. Use it to inspect a feature across the samples in this analysis. CPM values are not absolute transcript counts.

Evidence and verification

Pipeline QC passed. Mouse hypothalamus — risperidone (bulk RNA-seq); all 1 registered contrasts on default track hypothalamus

Experimental design passed. Mouse hypothalamus — risperidone (bulk RNA-seq); all 1 registered contrasts on default track hypothalamus

Author concordance not assessed. Author effect concordance has not been assessed

Pipeline QC can pass while experimental-design limitations remain. Read both assessments before interpreting results.

Open the dataset in the Explorer to read each check and its evidence. Author concordance compares effects for matched genes. It does not require identical author P values or FDR.

Read the analysis methods and interpretation guide and how to cite the source study and HypoExplorer. The source publication may include tissues, groups or comparisons beyond the data shown here.

Source study

Whole hypothalamus, control vs risperidone (ad-lib) — atypical antipsychotic targets central MC4R (GSE158751)

Source publication

The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.

Li L, Yoo ES, Li X, Wyler SC, Chen X, Wan R, et al.

The Journal of experimental medicine · 2021

Repository study title

The Atypical Antipsychotic Risperidone Targets Central Melanocortin 4 Receptors to Cause Weight

The original study authors produced these data. HypoExplorer displays selected data and analyses that may cover only part of the study.

How to cite the dataset, publication and HypoExplorer

Comparisons in HypoExplorer

Risperidone vs Control · default

Baseline: Control → Case: Risperidone

Positive differential-expression values indicate higher expression in the case group relative to the baseline. Check the comparison direction and study design when interpreting results.

Available tracks

Detected features and sample counts for Risperidone vs Control. Counts are specific to each track.
TrackFeaturesControl nRisperidone n
Whole hypothalamus17,20277

Expression and analysis results

Open this dataset to inspect gene expression and differential-expression results across the available tracks. Pathway enrichment is also available. The pathway databases differ by dataset.

HypoExplorer is in beta testing. Features and analyses may change during testing. Review the original source, analysis methods and quality-control checks before using a result in research.